Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 5/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739316 | 1.00 | PDE4B (0.33) | PDE4BPDE4DLIMK1ESR1ESR2 | |
| SCHEMBL5741839 | 0.84 | RXRA (0.37) | PDE4BPDE4DLIMK1 | |
| SCHEMBL5756237 | 0.80 | TDP1 (0.34) | RECQL | |
| SCHEMBL5756243 | 0.80 | TDP1 (0.34) | RECQL | |
| SCHEMBL5739318 | 0.80 | KIF11 (0.32) | PDE4BPDE4DLIMK1PRKCI | |
| SCHEMBL5740233 | 0.80 | LIMK1 (0.40) | PDE4BPDE4DLIMK1ESR1ESR2 | |
| SCHEMBL5738947 | 0.77 | LIMK1 (0.35) | PDE4BPDE4DLIMK1ESR1ESR2 | |
| SCHEMBL5740408 | 0.77 | SLC34A2 (0.35) | PDE4BPDE4DLIMK1ESR1ESR2 | |
| SCHEMBL6510139 | 0.77 | KMT2A (0.41) | PDE4BPDE4D | |
| SCHEMBL6504028 | 0.76 | MAPK14 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406891-B1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | HTT, HMOX1, SNCA | PDE4B 2513/4885PDE4D 3115/4885LIMK1 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.